Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
3.740
-0.010 (-0.27%)
Oct 29, 2025, 4:00 PM EDT - Market closed
Molecular Partners AG Revenue
Molecular Partners AG had revenue of 681.00K CHF in the twelve months ending June 30, 2025, down -91.34% year-over-year. In the year 2024, Molecular Partners AG had annual revenue of 4.97M, down -29.38%.
Revenue (ttm)
681.00K CHF
Revenue Growth
-91.34%
P/S Ratio
160.27
Revenue / Employee
4,297 CHF
Employees
159
Market Cap
137.24M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.97M | -2.07M | -29.38% |
| Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
| Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
| Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
| Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
MOLN News
- 2 months ago - EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 2 months ago - Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025 - GlobeNewsWire
- 4 months ago - Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 - GlobeNewsWire
- 5 months ago - Molecular Partners to cut workforce by a quarter - Reuters
- 5 months ago - Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway - GlobeNewsWire
- 5 months ago - Molecular Partners to Present at Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025 - GlobeNewsWire
- 7 months ago - Molecular Partners Announces all Board Proposals Approved at Annual General Meeting - GlobeNewsWire